Preterm birth (PTB) is the leading cause of neonatal mortality worldwide. Infection and inflammation are considered main causes of PTB. Among multiple pathogens, Gram-positive bacteria are commonly linked with induction of PTB. Although activation of innate immune responses, via TLR2 engagement, by Gram-positive bacteria is a likely cause, whether induction of PTB depends on the potency of specific microbial components to induce Toll-like receptor (TLR)2-driven inflammation has not been elucidated. Here, we show that TLR2 activation by synthetic lipopeptides, Pam2Cys, and Pam3Cys specifically, variably influenced inflammation and subsequent induction of PTB. Pam2Cys challenge, compared to Pam3Cys, induced PTB and promoted significantly higher expression of inflammatory cytokines, specifically IL-6 and IFN-, both in vivo and in vitro.
INTRODUCTION
Preterm birth (PTB) is a leading cause of infant morbidity and mortality worldwide. 1, 2 Although the etiology of PTB is multifactorial and remains largely enigmatic, it is well accepted that maternal inflammation, driven by infectious or noninfectious triggers, can play a critical role in preterm labor. 3 In fact, inflammation and immune activation are paramount for uterine activation and the onset of labor. 2 Pregnant women are more susceptible to infection by multiple pathogens, which increases the risk of severe illness and adverse pregnancy outcome. 2 Infections by Gram-positive bacteria have the most deleterious outcomes during pregnancy. 3, 4 Listeria monocytogenes, a Gram-positive bacteria and common contaminant of a variety of raw foods, has tropism for the placenta and is known to cause PTB in humans and mice. 3, 5 Moreover, Group B streptococci (GBS), the -hemolytic, Grampositive constituent of the normal vaginal microflora, is frequently Abbreviations: GBS, Group B streptococci; EPM, elicited peritoneal macrophage; PAMP, pathogen-associated molecular pattern; PTB, preterm birth; i.p., intraperitoneal associated with PTB. 6 Of note, Listeria species and GBS are pathogens that drive robust induction of proinflammatory cytokines including, IL-6, TNF, IFN-, and IFN-. [6] [7] [8] [9] [10] [11] Ureaplasma species (Ureaplasma parvum and Ureaplasma urealyticum) are Gram-positive bacteria commonly isolated from the female reproductive tract and in the amniotic fluid of pregnant women. 12 However, the contribution of Ureaplasma species to PTB is somewhat controversial. [12] [13] [14] [15] Size variation of the surfaceexposed lipopeptides on Ureaplasma species has been proposed to affect its ability to interact with innate immune receptors and impact consequent potency of immune response. 15 Hence, underlying causes of the propensity for certain Gram-positive bacterial species to trigger PTB are not well understood.
TLRs are a family of evolutionarily conserved innate immune receptors essential for recognition of microbial products. 16 Activation robustly expressed at the maternal/fetal interface by the pregnant uterus, placenta, amniotic membranes, and trophoblast. [19] [20] [21] [22] [23] In mice, challenge with diverse TLR ligands-via intraperitoneal, intrauterine, or intraamniotic routes-increases proinflammatory cytokine release in the uterus 5 and fetal membranes, 24, 25 recruits immune cells into the cervix, 26, 27 and induces PTB. [27] [28] [29] [30] [31] Notably, TLR2 is involved in the recognition of lipoteichoic acid and lipopeptides from Gram-positive bacteria. Specifically, the ability of TLR2 to heterodimerize with either TLR6 or TLR1 results in the recognition of diacylated and triacylated lipopeptides, respectively, hinting at a potential mechanism to discriminate among various microbial ligands and to elicit varied downstream inflammatory responses. However, the contribution of specific TLR2-activating lipopeptide species in the context of PTB has not been examined.
In this study, we hypothesized that induction of PTB depends on the potency of specific lipopeptides to induce TLR2-driven inflammation.
Our data demonstrate that recognition of diacylated lipopeptide (e.g., Pam2Cys) induced PTB and greater proinflammatory cytokine production compared to triacylated lipopeptide (e.g., Pam3Cys). Our data also suggest that sufficiency of inflammatory mediators to induce PTB following Pam2Cys or Pam3Cys challenge is varied. In sum, these data argue that TLR2-driven induction of PTB might depend on the magnitude and milieu of ligand-driven inflammatory vigor and such differences might shed light on why only certain Gram-positive bacterial species are associated with induction of PTB.
MATERIALS AND METHODS

Reagents
All cell culture reagents were endotoxin free to the limits of detection of the Limulus amebocyte lysate assay (Lonza, Visp, Switzerland) at the concentrations employed. All TLR ligands (Pam3Cys and Pam2Cys) used were of ultrapure grade (Invivogen, San Diego, CA).
Mice
Animals were housed in a specific pathogen-free animal facility at CCHMC and handled in high-efficiency particulate-filtered laminar flow hoods with free access to food and water. All studies were performed in accordance with the procedures outlined in the Guide for the Care and Use of Laboratory Animals and approved by the CCHMC Institutional Animal Care and Use Committee. Female mice (WT, IFNAR −/− ), on a C57BL/6J background, were mated with fertile male mice of the same strain. The presence of a vaginal plug was considered at day 1 of pregnancy. Parturition events were monitored on days 17-21 of gestation and defined as complete delivery of pups.
Preterm birth
On day 16 of gestation, gravid female mice were mock-challenged (saline) i.p. or challenged with Pam3Cys and Pam2Cys at indicated concentrations and treated with IL-6-neutralizing antibody (500 g/mouse; clone MP5-20F3; BioXCell, West Lebanon, NH) or recombinant mouse IL-6 (eBioscience, San Diego, CA) as indicated.
Exogenous administration of 10 4 U/mouse IFN-(PBL Biomedical Laboratories, Piscataway, NJ) was performed 4 h prior to Pam3Cys and Pam2Cys challenge and IL-6-neutralizing antibody administration.
PTB was defined as parturition within 24 h after TLR ligand challenge (all pups deceased). Term birth was defined as parturition between days 19 and 21 of gestation (all pups alive).
Cytokine quantification
In vivo systemic IL-6, TNF, and IFN-levels were quantified using in vivo cytokine capture assay. 5, 32, 33 Briefly, biotinylated capture antibodies (eBioscience) were injected i.p. 3 h prior to Pam3Cys and Pam2Cys administration and serum cytokine levels were determined 4 h later.
In vitro murine thioglycollate elicited peritoneal macrophages (EPMs) were generated using standard protocol. 5, 34 EPMs (1 × 10 6 cells/well) were cultured with or without IFN-(250 U/ml) for 4 h, subsequently mock-stimulated or stimulated with Pam3Cys (1.5 g/ml) or Pam2Cys (1.5 g/ml) for 4 h to determine mRNA expression, or with Pam3Cys (100 ng/ml) or Pam2Cys (100 ng/ml) for 18 h to determine cytokine production by ELISA (BD Biosciences, San Diego, CA).
Type I IFN activity quantification
Type I IFN activity in mouse serum samples or cell culture supernatants was measured with reference to a recombinant mouse IFN-using an L-929 cell line transfected with an IFN-sensitive luciferase construct as previously described. 5, 35 Luciferase activity was measured on a luminometer (SpectraMax L; Molecular Devices, Sunnyvale, CA).
Gene expression
For quantification of mRNA expression in murine samples, cells/tissues were homogenized in TRIzol (Invitrogen, San Diego, CA), RNA was extracted, and cDNA was generated and quantified as previously 
Statistical analysis
RESULTS AND DISCUSSION
Activation of TLR2 by Pam2Cys but not Pam3Cys induces PTB
Gram-positive bacteria (e.g., Listeria, GBS, and Ureaplasma species) are pathogens commonly associated with PTB. 5, 6, [12] [13] [14] [15] However, competency of certain bacteria to trigger PTB remains unclear. Although all experimental models of PTB have limitations compared to human pregnancy and parturition, mice represent the most common animal model of PTB. 2 Specifically, in such experimental models, the doses of inflammatory ligands employed are high. The intent being to enable 100% parturition incidence in fully backcrossed mice. 5, [36] [37] [38] [39] [40] Notably, that allows investigators to uncover differences between animal genotypes and/or various ligands in comparison to established baseline reads in wild-type (WT) mice. Here, we utilized a well-established, tractable, model of PTB induction in mice 5 for mechanistic insight into how early parturition is triggered in the context of systemic TLR2 challenge ( Figure 1A and B ). The pathways regulating immune responses are highly conserved between mice and humans-indicating that mice are a useful experimental tool for the interrogation of the role of infection/inflammation in induction of PTB. 21, 41 Further, in mice following i.p. TLR ligand injection, parturition-associated molecules are upregulated in the entire gestational environment and affect all fetuses. 5 Hence, the parturition process once initiated results in the delivery of all pups.
To overcome the complexity of a live bacterial infection (e.g., replication rate, tropism for various cell subsets, activation of multiple innate immune receptors), we used purified synthetic lipopeptides known to activate TLR2 signaling-pathogen-associated molecular patterns (PAMPs) that molecularly mimic the acylated amino terminus of bacterial lipopeptides. 42 Pregnant mice at day 16 of gestation were protected from PTB even at very high doses of triacylated lipopeptide (Pam3Cys; 1 mg/mouse) challenge ( Figure 1A) . Conversely, challenge with diacylated lipopeptide (Pam2Cys; 200 g/mouse) induced 100% PTB at the commonly used doses [43] [44] [45] ( Figure 1B ). In this experimental setting utilizing Pam2Cys challenge, all delivered pups died (either in utero or upon delivery) while the mothers survived the challenge without presenting apparent adverse outcomes that could hinder their health status. In mice, lung maturation is not fully completed at day 16 of gestation. 46 As our model invokes initiation of inflammatory insult at day 16 of gestation, the lack of lung maturation/function in prematurely born pups may represent the likely locus responsible for fetal death upon premature parturition. 36 As inflammation is directly linked with TLR-driven induction of PTB, the capacity of Pam2Cys and Pam3Cys to induce inflammatory responses was examined next. Induction of PTB by Pam2Cys correlated with significantly increased IL-6, IFN-, and IFN-, but similar TNF production compared to Pam3Cys challenge-findings when performed with equivalent doses of these TLR2 ligands ( Figure 1C ). The central role of proinflammatory cytokines, and IL-6 in particular, is supported by the correlation between IL-6 levels and PTB in humans 47 and in mouse models of TLR-driven inflammation. 5, 38 Pharmacological inhibition of IL-6 (antibody mediated) was sufficient to protect from Pam2Cys-driven PTB, while a single dose of rIL-6 alone or rIL-6 in combination with Pam3Cys was not sufficient to trigger induction of PTB ( Figure 1D )-something supported by a previously published report. 48 Such findings suggest that Pam2Cys and Pam3Cys signaling activate divergent immune mediators that may play a role in induction of PTB.
Further, these data also suggest that IL-6 is not the only proinflammatory cytokine upregulated in the context of PTB and that other immune mediators likely play a role in induction of PTB. Specifically, of interest to our findings, published reports suggest a role for IFN-in the regulation of mediators involved in the onset of labor. 49 Importantly, such
findings warrant that future studies should expand the knowledge of IFN-in inflammation-driven PTB.
Overall, our data suggest that Pam2Cys mediates a more potent TLR2-driven inflammatory response than Pam3Cys and that IL- 
Pam2Cys drives expression of type I IFN signature genes
Type In vivo stimulation by Pam2Cys led to increased IFN-production compared to Pam3Cys ( Figure 1C) . Similarly, in vitro stimulation of peritoneal macrophages by Pam2Cys triggered a more robust expression of IFN 1 and type I IFN signature genes (e.g., Mx1, Isg15, and IRF9) ( Figure 2A ). Further, this increase was concomitant with enhanced IL-6 and similar TNF mRNA levels compared to Pam3Cys ( Figure 2B ).
Although the type I IFN family in mice is composed of IFN-(with 14 known subtypes) and IFN-, TLR2-driven type I IFN-dependent responses are believed to be largely dependent on the activity of IFN-. 60 Notably, in agreement with the published report, IFN--deficient macrophages exhibit reduced IL-6 expression following Pam2Cys and Pam3Cys stimulation in vitro (data not shown). Moreover, we and others have shown that dysregulation of IFN-is a major determinant for PTB in context of a polymicrobial infection. 5, 62 However, the possible contribution of other type I IFNs (e.g., IFN-isotypes) has not been formally examined.
Although TLR2 activation was thought to specifically induce NF-kB-driven cytokine production, recently the contribution of endolysosomal TLR2 activation has been shown to promote type I IFN production. 60 However, the contribution of TLR2 homodimerization or dimerization of TLR2 with either TLR1 or TLR6 for induction of type I IFN is not known. 63 
IFNAR signaling contributes to Pam2Cys-mediated induction of PTB
Given the robust induction of type I IFN production and signature after Pam2Cys-driven TLR2 activation, the necessity of the common IFN / receptor (IFNAR) in proinflammatory cytokine production and PTB was further investigated. 64 IFNAR is a heteromeric cell surface receptor with 2 subunits, IFNAR1 and IFNAR2. Of note, IFN-specifically interacts with IFNAR1 in an IFNAR2-independent manner. 65 Compared to WT-treated mice, genetic deletion of IFNAR1 tempered Pam2Cys-dependent induction of IL-6 and TNF ( Figure 3A and B) and resulted in a 50% protection from Pam2Cys-driven PTB ( Figure   3C ). The lack of IFNAR1 signaling similarly decreased Pam3Cys-driven IL-6 and TNF production. Further Pam2Cys-driven cytokine production was significantly higher compared to Pam3Cys in both WT and IFNAR −/− mice ( Figure 3A and B) . These data suggest that both synthetic lipopeptides activate the type I IFN/IFNAR axis and that such activation regulates proinflammatory cytokine production in this context. However, although significant, the protection from Pam2Cysdriven PTB in IFNAR-deficient mice was not complete ( Figure 3C ), indicating that additional signaling pathways activated following Pam2Cys challenge are similarly involved. Hence, how IFNAR signaling (e.g., IFNAR1 and IFNAR2) contributes to protection from Pam2Cys-driven PTB warrants further investigation.
In fact, IFNAR modulation of chemokine production (e.g., CCL2 and 
IFN--driven enhancement of Pam3Cys-associated inflammation is not sufficient for induction of PTB
A combined recognition of viral and bacterial molecular patterns by TLR, coined a "double hit hypothesis", has been proposed as a central regulator of increased susceptibility to PTB. 40, 70, 71 We have previously demonstrated that type I IFNs regulates TLR4-driven inflammatory vigor, and specifically primes for exacerbated IL-6 and TNF production. 5 As Gram-positive bacteria-derived PAMPs are associated with PTB and robust activation of the type I IFN axis, we asked whether type I IFN priming acts as a universal sensitization mechanism to secondary challenge with all TLRs (including those that alone do not induce PTB). Of note, in vitro IFN-administration was sufficient, although at different levels, to prime for a secondary challenge with Pam2Cys and Pam3Cys ( Figure 4A ). This was recapitulated in vivo as IFN-priming exacerbated IL-6, TNF, and IFN-production by both Pam2Cys and Pam3Cys. However, IFN-priming induced significantly higher levels of proinflammatory cytokines upon secondary challenge with Pam2Cys ( Figure 4B and C) .
The relevance and sufficiency of such effects on PTB was examined next. IFN-sensitization was not sufficient to augment Pam3Cysdriven inflammatory vigor necessary for induction of PTB, even at very high concentration of ligand ( Figure 4D ). These data suggest that Pam2Cys and Pam3Cys have distinct functional consequences upon 
CONCLUSIONS
Overall, these data suggest that sufficiency of type I IFN priming in augmentation of inflammatory vigor, at least in conditions utilized in this report, is limited to certain secondary challenge. 5 
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